Dr John Fleming
Dr John Fleming, country medical director, Johnson & Johnson UK
HSJ PartnersTackling the systemic and economic burden of multiple myeloma in England
Multiple myeloma accounts for 15 per cent of all blood cancers and in recent years, its prevalence has risen sharply and is set to continue to increase by 67 per cent over the next 20 years.1,2